Epidemiology of skin cancer

Advances in Experimental Medicine and Biology

Volumn 810, Issue , 2014, Pages 120-140

  Leiter, Ulrike ^a   Eigentler, Thomas ^a   Garbe, Claus ^a  

^a UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BASAL CELL CARCINOMA; CANCER INCIDENCE; CANCER MORTALITY; CANCER RISK; CANCER SCREENING; CUTANEOUS MELANOMA; GERMANY; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; MELANOMA SKIN CANCER; NON MELANOMA SKIN CANCER; POPULATION RESEARCH; PRIORITY JOURNAL; SQUAMOUS CELL SKIN CARCINOMA; SUN EXPOSURE; TREND STUDY; ULTRAVIOLET A RADIATION; ULTRAVIOLET B RADIATION; EUROPE; FEMALE; INCIDENCE; MALE; MELANOMA; METABOLISM; PATHOLOGY; RADIATION EXPOSURE; RADIATION INDUCED NEOPLASM; REVIEW; RISK; SKIN; SKIN PIGMENTATION; SKIN TUMOR; SQUAMOUS CELL CARCINOMA; ULTRAVIOLET RADIATION;

CARCINOMA, BASAL CELL; CARCINOMA, SQUAMOUS CELL; EUROPE; FEMALE; HUMANS; INCIDENCE; MALE; MELANOMA; NEOPLASMS, RADIATION-INDUCED; RISK; SKIN; SKIN NEOPLASMS; SKIN PIGMENTATION; ULTRAVIOLET RAYS;

EID: 84907189508     PISSN: 00652598     EISSN: 22148019     Source Type: Book Series    
DOI: None     Document Type: Chapter

References (124)

1. Katalinic A, Kunze U, Schäfer T. Epidemiology of cutaneous melanoma and non-melanoma skin cancer in Schleswig-Holstein, Germany: incidence, clinical subtypes, tumour stages and localization(epidemiology of skin cancer). Br J Dermatol 2003; 149:1200-6; PMID:14674897; http://dx.doi.org/10.1111/j.1365-2133.2003.05554.x.
2. Diepgen TL, Mahler V. The epidemiology of skin cancer. Br J Dermatol 2002; 146(Suppl 61):1-6; PMID: 11966724; http://dx.doi.org/10.1046/j.1365-2133.146.s61.2.x.
3. Weinstock MA. Epidemiology of nonmelanoma skin cancer: clinical issues, definitions, and classification. J Invest Dermatol 1994; 102:4S-5S; PMID:8006434; http://dx.doi.org/10.1111/1523-1747.ep12385720.
4. Bauer A, Diepgen TL, Schmitt J. Is occupational solar ultraviolet irradiation a relevant risk factor for basal cell carcinoma? A systematic review and meta-analysis of the epidemiological literature. Br J Dermatol 2011; 165:612-25; PMID:21605109.
5. Schmitt J, Seidler A, Diepgen TL, Bauer A. Occupational ultraviolet light exposure increases the risk for the development of cutaneous squamous cell carcinoma: a systematic review and meta-analysis. Br J Dermatol 2011; 164:291-307; PMID:21054335; http://dx.doi.org/10.llll/j.1365-2133.2010.10118.x.
6. Diepgen TL, Fartasch M, Drexler H, Schmitt J. Occupational skin cancer induced by ultraviolet radiation and its prevention. Br J Dermatol 2012; 167(Suppl2):76-84; PMID:22881591; http://dx.doi.org/IO.l11l/j.l365-2133.2012.l1090.x.
7. Diepgen TL. Occupational skin diseases. JDtsch Dermatol Ges 2012; 10:297-313, quiz314-5;PMID:22455666; http://dx.doi.org/1 0.111l/j.1610-0387.2012.07890.x.
8. Armstrong BK, Kricker A, English DR. Sun exposure and skin cancer. Australas J Dermatol 1997; 38(Suppl 1):S1-6; PMID: 10994463.
9. Armstrong BK, Kricker A. The epidemiology of UV induced skin cancer. J Photochem Photobiol B JID-8804966 2001;63:8-18.
10. Mansson-Brahme E, Johansson H, Larsson O, Rutqvist LE, Ringborg U. Trends in incidence of cutaneous malignant melanoma in a Swedish population 1976-1994. Acta Oncol JID-8709065 1903;41:138-46.
11. Association of Population-based Cancer Registries in Germany (GEKID). Atlas of cancer incidence and mortality of the Association of Population-based Cancer Registries in Germany (GEKID), The GEKID Atlas". Results of the projection for Germany. 31-12-2011.
12. Eisemann N, Jansen L, Holleczek B, Waldmann A, Luttmann S, Emrich K, et al.; GEKID Survival Working Group. Up-to-date results on survival of patients with melanoma in Germany. Br J Dermatol 2012; 167:606-12; PMID:22564081; http://dx.doi.org/10.1111/j.1365-2133.2012.11039.x.
13. Bosetti C, La Vecchia C, Naldi L, Lucchini F, Negri E, Levi F. Mortality from cutaneous malignant melanoma in Europe. Has the epidemic levelled off? Melanoma Res 2004; 14:301-9; PMID: 15305162; http://dx.doi.org/10.1097/01.cmr.0000136710.75287.1c.
14. Forsea AM, Del Marmo! V, de Vries E, Bailey EE, Geller AC. Melanoma incidence and mortality in Europe: new estimates, persistent disparities. Br J Dermatol2012; 167:1124-30; PMID:22759278; http://dx.doi.org/10.l11l/j.1365-2133.2012.l1125.x.
15. Katalinic A, Waldmann A, Weinstock MA, Geller AC, Eisemann N, Greinert R, et al. Does skin cancer screening save lives?: an observational study comparing trends in melanoma mortality in regions with and without screening. Cancer 2012; 118:5395-402; PMID:22517033; http://dx.doi.org/10.1002/cncr.27566.
16. Gray DT, Suman VJ, Su WP, Clay RP, Harmsen WS, Roenigk RK. Trends in the population-based incidence of squamous cell carcinoma of the skin first diagnosed between 1984 and 1992. Arch Dermatol 1997; 133:735-40; PMID:9197827; http://dx.doi.org/10.100l/archderm.1997.03890420073008.
17. Hannuksela-Svahn A, Pukkala E, Karvonen J. Basal cell skin carcinoma and other nonmelanoma skin cancers in Finland from 1956 through 1995. Arch Dermatol 1999; 135:781-6; PMID:10411152; http://dx.doi.org/10.1001/archderm.135.7.781.
18. Iversen T, Tretli S. Trends for invasive squamous cell neoplasia of the skin in Norway. Br J Cancer 1999; 81:528-31; PMID: 10507780; http://dx.doi.org/10.1038/sj.bjc.6690725.
19. Karagas MR, Greenberg ER, Spencer SK, Stukel TA, Mott LA; New Hampshire Skin Cancer Study Group. Increase in incidence rates ofbasal cell and squamous cell skin cancer in New Hampshire, USA. Int J Cancer 1999;81:555-9;PMID: 10225444; http://dx.doi.org/10.1002/(SICI)1097-0215(19990517)81:4<555::AID­ IJC9>3.0.C0;2-R.
20. Staples M, Marks R, Giles G. Trends in the incidence of non-melanocytic skin cancer (NMSC) treated in Australia 1985-1995: are primary prevention programs starting to have an effect? Int J Cancer 1998; 78: 144-8; PMID:9754642; http://dx.doi.org/10.1002/(SICI)1097-0215(19981005)78:2<144::AID­IJC3>3.0.C0;2-Z.
21. Lomas A, Leonardi-Bee J, Bath-Hextall F. A systematic review of worldwide incidence ofnonmelanoma skin cancer. Br J Dermatol 2012; 166:1069-80; PMID:22251204; http://dx.doi.org/10.1111j.1365-2133.2012.l0830.x.
22. Green A, Marks R. Squamous cell carcinoma of the skin (non-metastatic). Clin Evid 2005:2086-90; PMID:16620483.
23. Stem RS. The mysteries of geographic variability in nonmelanoma skin cancer incidence. Arch Dermatol 1999; 135:843-4; PMID:10411160; http://dx.doi.org/10.1001/archderm.135.7.843.
24. Stem RS. Prevalence of a history of skin cancer in 2007: results of an incidence-based model. Arch Dermatol 2010; 146:279-82; PMID:20231498; http://dx.doi.org/10.1001/archdermatol.2010.4.
25. Green A, Mac Lennan R, Youl P, Martin N. Site distribution of cutaneous melanoma in Queensland. Int J Cancer 1993; 53:232-6; PMID:8425760; http://dx.doi.org/10.1002/ijc.2910530210.
26. Buettner PG, Raasch BA. Incidence rates of skin cancer in Townsville, Australia. Int J Cancer 1998; 78:587-93; PMID:9808527; http://dx.doi.org/10.1002/(SICI) 1097-0215(19981123)78:5<587::AID­IJC10>3.0. C0;2-E.
27. Birch-Johansen F, Jensen A, Mortensen L, Olesen AB, Kjrer SK. Trends inthe incidence ofnonmelanoma skin cancer in Denmark 1978-2007: Rapid incidence increase among young Danish women. Int J Cancer 2010; 127:2190-8; PMID:20473901; http://dx.doi.org/10.1002/ijc.25411.
28. Holme SA, Malinovsky K, Roberts DL. Malignant melanoma in South Wales: changing trends in presentation (1986-98). Clin Exp Dermatol n D-7606847 2001;26:484-9.
29. Athas WF, Hunt WC, Key CR. Changes innonmelanomaskin cancer incidence between 1977-1978 and 1998-1999in Northcentral New Mexico. Cancer Epidemiol Biomarkers Prev 2003; 12:1105-8; PMID: 14578151.
30. Raasch BA, Buettner PG. Multiple nonmelanoma skin cancer in an exposed Australian population. Int J Dermatol 2002; 41:652-8; PMID:12390187; http://dx.doi.org/10.1046/j.l365-4362.2002.01573.x.
31. Katalinic A. [Population-based cancer registration in Germany. Essentials and perspectives]. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz 2004; 47:422-8; PMID:15205754; http://dx.doi.org/1 0.1007/s OO 103-004-0827-2.
32. Lewis KG, Weinstock MA. Trends in nonmelanoma skin cancer mortality rates in the United States, 1969 through 2000. J Invest Dermatol 2007; 127:2323-7; PMID:17522705; http://dx.doi.org/10.1038/sj.jid.5700897.
33. Stang A, Jöckel KH. Declining mortality rates for nonmelanoma skin cancers in West Germany, 1968-99. Br J Dermatol 2004; 150:517-22;PMID: 15030336;http://dx.doi.org/10.1046/j.1365-2133.2004.05831.x.
34. Hollestein LM, de Vries E, Nijsten T. Trends of cutaneous squamous cell carcinoma in the Netherlands: increased incidence rates, but stable relative survival and mortality 1989-2008. Eur 1 Cancer 2012; 48:2046-53; PMID:22342554; http://dx.doi.org/10.1016/j.ejca.2012.01.003.
35. Lehnert M, Eberle A, Hentschel S, Katalinic A, Kieschke J, Schmidtmann I, et al. [Malignant melanoma of the skin as evidenced by epidemiological cancer registries in Germany--incidence, clinical parameters, variations in recording]. Gesundheitswesen 2005; 67:729-35; PMID: 16235142; http://dx.doi.org/10.1055/s-2005-858696.
36. de Villiers EM. Human papillomavirus infections in skin cancers. Biomed Pharmacother 1998; 52:26-33; PMID:975 5792; http://dx.doi.org/10.1016/S0753-3322(97)86238-5.
37. Ziegler A, Leffell DJ, Kunala S, Sharma HW, Gailani M, Simon JA, et al. Mutation hotspots due to sunlight in the p53 gene ofnonmelanoma skin cancers. Proc Natl Acad Sci US A 1993; 90:4216-20; PMID:8483937; http://dx.doi.org/10.1073/pnas.90.9.4216.
38. Zhang H, Ping XL, Lee PK, Wu XL, Yao YI, Zhang MJ, et al. Role of PTCH and p53 genes in early­ onset basal cell carcinoma. Am J Pathol 2001; 158:381-5; PMID: 11159175; http://dx.doi.org/10.1016/S0002-9440(10)63980-6.
39. Athar M, Tang X, Lee JL, Kopelovich L, Kim AL. Hedgehog signalling in skin development and cancer. Exp Dermato1 2006; 15:667-77; PMID:16881963; http://dx.doi.org/10.1111/j.1600-0625.2006.00473.x.
40. Daya-Grosjean L, Sarasin A. UV-specific mutations of the human patched gene in basal cell carcinomas from normal individuals and xeroderma pigmentosum patients. Mutat Res 2000; 450: 193-9;PMID: 10838143; http://dx.doi.org/10.1016/S0027-5107(00)00025-7.
41. Brantsch KD, Meisner C, Schönfisch B, Trilling B, Wehner-Caroli J, Röcken M, et al. Analysis of risk factors determining prognosis of cutaneous squamous-cell carcinoma: a prospective study. Lancet Oncol 2008; 9:713-20; PMID: 18617440; http://dx.doi.org/10.1016/S1470-2045(08)70178-5.
42. English DR, Armstrong BK, Kricker A, Winter MG, Heenan PJ, Randell PL. Case-control study of sun exposure and squamous cell carcinoma of the skin. Int J Cancer 1998; 77:347-53; PMID:9663594; http://dx.doi.org/10.1002/(SICI)1097-0215(19980729)77:3<347::AID-IJC7>3.0.C0;2-0.
43. Kricker A, Armstrong BK, English DR. Sun exposure and non-melanocytic skin cancer. Cancer Causes Control 1994; 5:367-92; PMID:8080949; http://dx.doi.org/10.1007/BF01804988.
44. Kricker A, Armstrong BK, Mc Michaei AJ. Skin cancer and ultraviolet. Nature 1994;368:594;PMID:8145844; http://dx.doi.org/10.1038/368594b0.
45. Kricker A, Armstrong BK, English DR, Heenan PJ. A dose-response curve for sun exposure and basal cell carcinoma Int J Cancer 1995; 60:482-8; PMID:7829261; http://dx.doi.org/10.1002/ijc.2910600410.
46. English DR, Armstrong BK, Kricker A, Winter MG, Heenan PJ, Randell PL. Demographic characteristics, pigmentary and cutaneous risk factors for squamous cell carcinoma of the skin: a case-control study. Int J Cancer 1998; 76:628-34; PMID:9610717; http://dx.doi.org/10.1002/(SICI)I097-0215(19980529)76:5<628::AID-IJC3>3.0. C0;2-S.
47. Levanat S, Mubrin MK, Crnić I, Situm M, Basta-Juzbasić A. Variable expression of Gorlin syndrome may reflect complexity of the signalling pathway. Pflugers Arch 2000; 439(Suppl):R31-3; PMID: 10653132; http://dx.doi.org/1 0.1007/s004240000080.
48. Situm M, Levanat S, Crnic I, Pavelic B, Macan D, Grgurević J, et al. Involvement of patched (PTCH) gene in Gorlin syndrome and related disorders: three family cases. Croat Med J 1999;40:533-8; PMID: 10554356.
49. Ping XL, Ratner D, Zhang H, Wu XL, Zhang MJ, Chen FF, et al. PTCH mutations in squamous cell carcinoma of the skin. J Invest Dermato1 2001; 116:614-6; PMID:l1286632; http:l/dx.doi.org/10.1046/j.1523-1747.2001.0130l.x.
50. Ling G, Ahmadian A, Persson A, Undén AB, Afink G, Williams C, et al. PATCHED and p53 gene alterations in sporadic and hereditary basal cell cancer. Oncogene 2001; 20:7770-8; PMID:11753655; http://dx.doi.org/10.1038/sj.onc.1204946.
51. Green A, Williams G, Neale R, Hart V, Leslie D, Parsons P, et al. Daily sunscreen application and betacarotene supplementation in prevention of basal-cell and squamous-cell carcinomas of the skin: a randomised controlled trial. Lancet 1999; 354:723-9; PMID:10475183; http://dx.doi.org/10.1016/S0140-6736(98)12168-2.
52. Summary of the NIH consensus diagnosis and treatment of early melanoma. Pa Nurse 1992; 47:9; PMID: 1470475.
53. Bulliard JL, Cox B, Semenciw R. Trends by anatomic site in the incidence of cutaneous malignant melanoma in Canada, 1969-93. Cancer Causes Control 1999; 10:407-16; PMID: 10530611; http://dx.doi.org/10.1023/A:1008964621225.
54. de Vries E, Bray FI, Coebergh JW, Parkin DM. Changing epidemiology of malignant cutaneous melanoma in Europe 1953-1997: rising trends in incidence and mortality but recent stabilizations in western Europe and decreases in Scandinavia. Int J Cancer 2003; 107: 119-26;PMID: 12925966; http://dx.doi.org/10.1002/ijc.l1360.
55. Dennis LK. Melanoma incidence by body site: effects of birth-cohort adjustment. Arch Dermatol 1999; 135:1553-4; PMID: 10606076; http://dx.doi.org/10.1001/archderm.135.12.1553.
56. Geller AC, Miller DR, Annas GD, Demierre MF, Gilchrest BA, Koh HK. Melanoma incidence and mortality among US whites, 1969-1999. JAMA 2002; 288:1719-20; PMID:12365954; http://dx.doi.org/10.1001/jama.288.14.1719.
57. Hall HI, Miller DR, Rogers JD, Bewerse B. Update on the incidence and mortality from melanoma in the United States. JAm Acad Dermatol 1999; 40:35-42; PMID:9922010; http://dx.doi.org/10.1016/S0190-9622(99)70562-l.
58. Marrett LD, Nguyen HL, Armstrong BK. Trends in the incidence of cutaneous malignant melanoma in New South Wales, 1983-1996. Int J Cancer 2001; 92:457-62; PMID: 11291086; http://dx.doi.org/10.1 002/ijc.l203.
59. Gondos A, Bray F, Brewster DH, Coebergh JW, Hakulinen T, Janssen-Heijnen ML, et al.; EUNICE Survival Working Group. Recent trends in cancer survival across Europe between 2000 and 2004: a model-based period analysis from 12cancer registries. Eur J Cancer 2008; 44: 1463-75; PMID: 18455387; http://dx.doi.org/10.1016/j.ejca.2008.03.010.
60. Jemal A, Saraiya M, Patel P, Cherala SS, Bamholtz-Sioan J, Kim J, et al. Recent trends in cutaneous melanoma incidence and death rates in the United States, 1992-2006. JAm Acad Dermatol 2011;65(Suppl l):S17-25, e1-3; PMID:22018063; http://dx.doi.org/10.1016/j.jaad.2011.04.032.
61. Jones WO, Harman CR, Ng AK, Shaw JH. Incidence of malignant melanoma in Auckland, New Zealand: highest rates in the world. World J Surg 1999; 23:732-5; PMID:10390596; http://dx.doi.org/10.1007/P100012378.
62. MacLennan R, Green AC, McLeod GR, Martin NG. Increasing incidence of cutaneous melanoma in Queensland, Australia JNatl Cancer Inst 1992; 84: 1427-32; PMID: 1512795; http://dx.doi.org/10.1093/jnci/84.18.1427.
63. Marks R. Epidemiology of melanoma. Clin Exp Dermatol 2000; 25:459-63; PMID: 11044179; http://dx.doi.org/10.1046/j.1365-2230.2000.00693.x.
64. Jhappan C, Noonan FP, Merlino G. Ultraviolet radiation and cutaneous malignant melanoma Oncogene 2003; 22:3099-112; PMID: 12789287; http://dx.doi.org/10.1038/sj.onc.l206450.
65. Balzi D, Carli P, Giannotti B, Paci E, Buiatti E. Cutaneous melanoma in the Florentine area, Italy: incidence, survival and mortality between 1985 and 1994. Eur J Cancer Prev 2003; 12:43-8; PMID: 12548109; http://dx.doi.org/10.1097/00008469-200302000-00007.
66. Ocaña-Riola R, Martinez-Garcia C, Serrano S, Buendía-Eisman A, Ruiz-Baena C, Canela-Soler J. Population-based study of cutaneous malignant melanoma in the Granada province (Spain), 1985-1992. Eur J Epidemiol 2001; 17:169-74; PMID: 11599692; http://dx.doi.org/10.1023/A: 1017930504671.
67. Vinceti M, Rothman KJ, Bergomi M, Borciani N, Serra L, Vivoli G. Excess melanoma incidence in a cohort exposed to high levels of enviromnental selenium. Cancer Epidemiol Biomarkers Prev 1998; 7:853-6; PMID:9796628.
68. de Vries E, van de Poll-Franse LV, Louwman WJ, de Gruijl FR, Coebergh JW. Predictions of skin cancer incidence in the Netherlands up to 2015. Br J Dermato1 2005; 152:481-8; PMID:15787817; http://dx.doi.org/10.1111/j.1365-2133.2005.06386.x.
69. Association of Population-based Cancer Registries in Germany (GEKID). 2011 1109/id.
70. Stang A, Jöckel KH. Changing patterns of skin melanoma mortality in West Germany from 1968through 1999. Ann Epidemiol 2003; 13:436-42; PMID:12875802; http://dx.doi.org/10.1016/S1047-2797(03)00002-4.
71. ACT Cancer Registry, ACT Health 2009 Cancer in the ACT 2002-06. ACTGovernment Canberra ACT. Cancer in the ACT Incidence and Mortality 2009. Australian Capital Territory, Canberra, August 2009. 15-8-2009.
72. Berwick M, Erdei EO. Vitamin D and Melanomalncidence and Mortality. Pigment Ceii Melanoma Res. 2012.
73. Mackie RM, Marks R, Green A. The melanomaepidemic. Excess exposure to ultraviolet light is established as major risk factor. BMJ 1996;312: 1362-3;PMID:8646075;http://dx.doi.org/10.1136/bmj.312.7042.1362b.
74. de Vries E, Schouten LJ, Visser O, Eggermont AM, Coebergh JW; Working Group of Regional Cancer Registries. Rising trends in the incidence of and mortality from cutaneous melanoma in the Netherlands: a Northwest to Southeast gradient? Eur J Cancer 2003; 39:1439-46; PMID:12826048; http://dx.doi.org/10.1016/S0959-8049(03)00320-4.
75. Buettner PG, Leiter U, Eigentler TK, Garbe C. Development of prognostic factors and survival in cutaneous melanoma over 25 years: An analysis of the Central Malignant Melanoma Registry of the German Dermatological Society. Cancer 2005; 103:616-24; PMID: 15630700;http://dx.doi.org/10.1002/cncr.20816.
76. Garbe C, Mc Leod GR, Buettner PG. Time trends of cutaneous melanoma in Queensland, Australia and Central Europe. Cancer 2000; 89:1269-78; PMID:l1002222; http://dx.doi.org/10.1002/1097-0142(20000915)89:6<1269::AID-CNCR11>3.0.CO;2-C.
77. De Rooij MJ, Rampen FH, Schouten LJ, Neumann HA. Total skin examination during screening for malignant melanoma does not increase the detection rate. Br J Dermatol 1996; 135:42-5; PMID:8776357; http://dx.doi.org/10.1111/j.1365-2133.1996.tb03605.x.
78. Schneider JS, Moore DH 2"'\ Mendelsohn ML. Screening program reduced melanoma mortality at the Lawrence Livermore National Laboratory, 1984 to 1996. JAm Acad Dermatol 2008; 58:741-9; PMID: 18068264; http://dx.doi.org/10.1016/j.jaad.2007.10.648.
79. Stratigos A, Nikolaou V, Kedicoglou S, Antoniou C, Stefanaki I, Haidemenos G, et al. Melanoma/skin cancer screening in a Mediterranean country: results of the Euromelanoma Screening Day Campaign in Greece. JEur Acad Dermatol Venereol 2007;21:56-62;PMID: 17207168;http://dx.doi.org/10.1111/j.1468-3083.2006.01865.x.
80. Garbe C, Büttner P, Bertz J, Burg G, d'Hoedt B, Drepper H, et al. Primary cutaneous melanoma. Prognostic classification of anatomic location. Cancer 1995; 75:2492-8; PMID:7736393; http://dx.doi.org/10.100211097-0142(19950515)75:10<2492::AID-CNCR2820751015>3.0.C0;2-W.
81. Garbe C, Blum A. Epidemiology of cutaneous melanoma in Germany and worldwide. Skin Pharmacol Appl Skin Physiol 2001; 14:280-90; PMID:11586069; http://dx.doi.org/10.1159/000056358.
82. Garbe C, Leiter U. Melanoma epidemiology and trends. Clin Dermatol 2009; 27:3-9; PMID:19095149; http://dx.doi.org/1 0.1016/j.clindermato1.2008.09.001.
83. Garbe C, Buttner P, Ellwanger U, Orfanos CE. [Management of primary malignant melanoma of the skin in German-speaking countries 1983-1993. A study of the Malignant Melanoma Central Register of the German Society of Dermatology]. Hautarzt 1995;46:762-70; PMID:8641882; http://dx.doi.org/10.1007/s001050050336.
84. Erdmann F, Lortet-Tieulent J, Schüz J, Zeeb H, Greinert R, Breitbart EW, et al. International trends in the incidence of malignant melanoma 1953-2008--are recent generations at higher or lower risk? Int J Cancer 2013; 132:385-400; PMID:22532371.
85. Waldmann A, Nolte S, Weinstock MA, Breitbart EW, Eisemann N, Geller AC, et al. Skin cancer screening participation and impact on melanoma incidence in Germany--an observational study on incidence trends in regions with and without population-based screening. Br J Cancer 2012; 106:970-4; PMID:22294187; http://dx.doi.org/10.1038/bjc.2012.22.
86. Weir HK, Marrett LD, Cokkinides V, Bamholtz-Sioan J, Patel P, Tai E, et al. Melanoma in adolescents and young adults (ages 15-39 years): United States, 1999-2006. JAm Acad Dermatol 2011; 65(Suppl 1):S38-49; PMID:220 18066; http://dx.doi.org/10.1016/j.jaad.2011.04.038.
87. Lasithiotakis K, Leiter U, Meier F, Eigentler T, Metzler G, Moehrle M, et al. Age and gender are significant independent predictors of survival in primary cutaneous melanoma. Cancer 2008; 112:1795-804; PMID: 18306371; http://dx.doi.org/1 0.1002/cncr.23359.
88. Lasithiotakis KG, Leiter U, Gorkievicz R, Eigentler T, Breuninger H, Metzler G, et al. The incidence and mortality of cutaneous melanoma in Southern Germany: trends by anatomic site and pathologic characteristics, 1976 to 2003. Cancer 2006; 107:1331-9; PMID:16909413; http://dx.doi.org/10.1002/cncr.22126.
89. Carli P, Borgognoni L, Biggeri A, Carli S, Reali UM, Giannotti B. Incidence of cutaneous melanoma in the centre of Italy: anatomic site distribution, histologic types and thickness of tumour invasion in a registry-basedstudy. Melanoma Res 1994;4:385-90; PMID: 7703718; http://dx.doi.org/10.1097/00008390-199412000-00007.
90. Hoersch B, Leiter U, Garbe C. Is head and neck melanoma a distinct entity? A clinical registry-based comparative study in 5702 patients with melanoma. Br J Dermatol 2006; 155:771-7; PMID:16965427; http://dx.doi.org/10.1111/j.1365-2133.2006.07455.x.
91. Whiteman DC, Stickley M, Watt P, Hughes MC, Davis MB, Green AC. Anatomic site, sun exposure, and risk of cutaneous melanoma. J Clin Oncol 2006; 24:3172-7; PMID: 16809740; http://dx.doi.org/10.1200/JC0.2006.06.1325.
92. Elwood JM, Jopson J. Melanoma and sun exposure: an overview of published studies. Int J Cancer 1997; 73: 198-203; PMID:9335442; http://dx.doi.org/10.1002/(SICI)1097-0215(19971009)73:2<198::AID­IJC6>3.0.CO;2-R.
93. Gandini S, Sera F, Cattaruzza MS, Pasquini P, Picconi O, Boyle P, et al. Meta-analysis of risk factors for cutaneous melanoma: II. Sun exposure. Eur J Cancer 2005; 41:45-60; PMID:l5617990; http://dx.doi.org/10.10l6/j.ejca.2004.10.016.
94. Garibyan L, Fisher DE. How sunlight causes melanoma. Curr Oncol Rep 2010; 12:319-26;PMID:20623386; http://dx.doi.org/10.1007/s11912-0l0-0119-y.
95. Hodis E, Watson IR, Kryukov GV, Arold ST, Imielinski M, Theurillat JP, etal. Alandscapeofdrivermutations in melanoma. Cell 2012; 150:251-63; PMID:22817889; http://dx.doi.org/10.1016/j.cell.2012.06.024.
96. Garbe C, Büttner P, Weiss J, Soyer HP, Stocker U, Krüger S, et al. Associated factors in the prevalence of more than 50 common melanocytic nevi, atypical melanocytic nevi, and actinic lentigines: multicenter case-control study of the Central Malignant Melanoma Registry of the German Dermatological Society. J Invest Dermatol 1994; 102:700-5; PMID:8176251; http://dx.doi.org/10.111111523-l747.epl2374298.
97. Wiecker TS, Luther H, Buettner P, Bauer J, Garbe C. Moderate sun exposure and nevus counts in parents are associated with development of melanocytic nevi in childhood: a risk factor study in l,812 kindergarten children. Cancer 2003; 97:628-38; PMID: 12548604; http://dx.doi.org/10.1002/cncr.11114.
98. Bauer J, Büttner P, Wiecker TS, Luther H, Garbe C. Interventional study in 1,232young German children to prevent the development of melanocytic nevi failed to change sun exposure and sun protective behavior. Int J Cancer 2005; 116:755-61; PMID:l5849749; http://dx.doi.org/10.1002/ijc.21081.
99. Bauer J, Büttner P, Wiecker TS, Luther H, Garbe C. Effect of sunscreen and clothing on the number ofmelanocytic nevi in 1,812 German children attending day care. Am J Epidemiol 2005; 161:620-7; PMID: 15781951; http://dx.doi.org/10.1093/ajelkwi086.
100. Eide MJ, Weinstock MA. Association of UV index, latitude, and melanoma incidence in nonwhite populations--US Surveillance, Epidemiology, and End Results (SEER) Program, 1992 to 2001. Arch Dermatol 2005; 141:477-81; PMID: 15837865; http://dx.doi.org/10.100l/archderm.141.4.477.
101. Parkin DM, Pisani P, Ferlay J. Estimatesoftheworldwide incidence of25 major cancers in 1990. Int J Cancer 1999;80:827-41; PMID: 10074914; http://dx.doi.org/10.1002/(SICI)1097-0215(19990315)80:6<827::AID­ IJC6>3.0.C0;2-P.
102. Rigel DS, Carucci JA. Malignant melanoma: prevention, early detection, and treatment in the 21st century. CA Cancer J Clin 2000; 50:215-36, quiz 237-40; PMID:10986965; http://dx.doi.org/10.3322/canjclin.50.4.215.
103. Autier P, Doré JF, Gefeller O, Cesarini JP, Lejeune F, Koelmel KF, et al.; EORTC Melanoma Co-operative Group. European Organization for Research and Treatment of Cancer. Melanoma risk and residence in sunny areas. Br J Cancer 1997; 76:1521-4; PMID:9400952; http://dx.doi.org/10.1038/bjc.1997.588.
104. De Fabo EC, Noonan FP, Fears T, Merlino G. Ultraviolet B but not ultraviolet A radiation initiates melanoma. Cancer Res 2004; 64:6372-6; PMID:l537494l; http://dx.doi.org/10.1158/0008-5472.CAN-04-1454.
105. Thomas NE, Edmiston SN, Alexander A, Millikan RC, Groben PA, Hao H, et al. Number of nevi and early­ life ambient UV exposure are associated with BRAF-mutant melanoma. Cancer Epidemiol Biomarkers Prev 2007; 16:991-7; PMID: 17507627; http://dx.doi.org/10.1158/1055-9965.EPI-06-1038.
106. Wang SQ, Setlow R, Berwick M, Polsky D, Marghoob AA, Kopf AW, et al. Ultraviolet A and melanoma: a review. J Am Acad Dermatol 2001; 44:837-46; PMID: 11312434; http://dx.doi.org/10.1067/mjd.200l.l14594.
107. Thomas NE, Berwick M, Cordeiro-Stone M. Could BRAF mutations in melanocytic lesions arise from DNA damage induced by ultraviolet radiation? J Invest Dermatol 2006; 126:1693-6; PMID:l6845408; http://dx.doi.org/10.1038/sj.jid.5700458.
108. Dong J, Phelps RG, Qiao R, Yao S, Benard O, Ronai Z, et al. BRAF oncogenic mutations correlate with progression rather than initiation of human melanoma. Cancer Res 2003; 63:3883-5; PMID: 12873977.
109. Kumar R, Angelini S, Snellman E, Hemminki K. BRAF mutations are common somatic events in melanocyticnevi. Jinvest Dermatol 2004; 122:342-8;PMID:l5009715;http://dx.doi.org/10.1046/j.0022-202X.2004.22225. X.
110. Pollock PM, Harper UL, Hansen KS, Yudt LM, Stark M, Robbins CM, et al. High frequency of BRAF mutations in nevi. Nat Genet 2003; 33:19-20; PMID: 12447372; http://dx.doi.org/10.1038/ng1054.
111. Yazdi AS, Palmedo G, Flaig MJ, Puchta U, Reckwerth A, Rutten A, et al. Mutations of the BRAF gene in benign and malignant melanocytic lesions. J Invest Dermatol 2003; 121:1160-2; PMID:l4708620; http://dx.doi.org/10.1046/j.l523-1747.2003.12559.x.
112. Monzon J, Liu L, Brill H, Goldstein AM, Tucker MA, From L, et al. CDKN2A mutations in multiple primary melanomas. N Engl J Med 1998; 338:879-87; PMID:9516223; http://dx.doi.org/10.1056/NEJM199803263381305.
113. Maldonado JL, Fridlyand J, Patel H, Jain AN, Busam K, Kageshita T, et al. Determinants of BRAF mutations in primary melanomas. J Natl Cancer Inst 2003; 95:1878-90; PMID:l4679157; http://dx.doi. org/10.1093/jnci/djgl23.
114. Miller AJ, Mihm MC Melanoma. N Engl J Med 2006; 355:51-65; PMID:l6822996; http://dx.doi.org/10.1056/NEJMra052166.
115. Zimmer L, Hillen U, Livingstone E, Lacouture ME, Busam K, Carvajal RD, et al. Atypical melanocytic proliferations and new primary melanomas in patients with advanced melanoma undergoing selective BRAF inhibition. J Clin Oncol 2012;30:2375-83;PMID:22614973; http://dx.doi.org/10.1200/JC0.2011.41.1660.
116. Holman CD, Armstrong BK. Cutaneous malignant melanoma and indicators oftotal accumulated exposure to the sun: an analysis separating histogenetic types. J Natl Cancer Inst 1984; 73:75-82; PMID:6588237.
117. Hu S, Ma F, Collado-Mesa F, Kirsner RS. UV radiation, latitude, and melanoma in US Hispanics and blacks. Arch Dermatol2004; 140:819-24;PMID: 15262692; http://dx.doi.org/10.100llarchderm.140.7.819.
118. Whiteman DC, Whiteman CA, Green AC. Childhood sun exposure as a risk factor for melanoma: a systematic review of epidemiologic studies. Cancer Causes Control 2001; 12:69-82; PMID:ll227927; http://dx.doi.org/10.1023/A:1008980919928.
119. Holman CD, Armstrong BK, Heenan PJ. A theory of the etiology and pathogenesis of human cutaneous malignant melanoma. J Natl Cancer Inst 1983; 71:651-6; PMID:6578359.
120. Gilchrest BA, Eller MS, Geller AC, Yaar M. The pathogenesis of melanoma induced by ultraviolet radiation. N Engl J Med 1999; 340:1341-8; PMID:10219070; http://dx.doi.org/10.1056/NEJM199904293401707.
121. Berger MF, Hodis E, Heffernan TP, Deribe YL, Lawrence MS, Protopopov A, et al. Melanoma genome sequencing reveals frequent PREX2 mutations. Nature 2012; 485:502-6; PMID:22622578.
122. Pleasance ED, Cheetham RK, Stephens PJ, Mc Bride DJ, Humphray SJ, Greenman CD, et al. A comprehensive catalogue of somatic mutations from a human cancer genome. Nature 2010; 463:191-6; PMID:20016485; http://dx.doi.org/10.1038/nature08658.
123. Zaidi MR, Davis S, Noonan FP, Graff-Cherry C, Hawley TS, Walker RL, et al. Interferon-y links ultraviolet radiation to melanomagenesis in mice. Nature 2011; 469:548-53; PMID:21248750; http://dx.doi.org/10.1038/nature09666.
124. Dérijard B, Hibi M, Wu IH, Barrett T, Su B, Deng T, et al. JNKl: a protein kinase stimulated by UV light and Ha-Ras that binds and phosphorylates the c-Jun activation domain. Cell 1994; 76:1025-37; PMID: 8137421; http://dx.doi.org/10.1016/0092-8674(94)90380-8.